Skip to main content
S&P 5007,551.81-0.45%DOW51,461.90-1.21%NASDAQ25,978.42-0.01%BTC$76,760.00+1.42%ETH$2,459.67+2.60%GOLD$4,413.80+0.60%OIL$99.75-2.62%
Smart Investors Daily
VN

NASDAQ · VNRX

VolitionRx Limited

Healthcare · Medical - Diagnostics & Research

$0.27

Down-$0.01 (-4.98%)

Updated Sep 17, 2026, 1:08 PM

SID Score

3.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
28.3M
P/E ratio
-1.34
Dividend yield
0.00%
52-week range
$0.28 – $14.80
Volume
1.44M
Avg. volume
1.34M

Price performance

VNRX price history

1M range · 20 trading sessions · Daily adjusted prices

VNRX closed at $0.27 after 20 trading sessions, down 43.68% for the selected period.

Last close
$0.27
Period change
-43.68%
Period low
$0.27
Period high
$0.50
Daily close
View OHLC price history
VNRX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 16, 2026$0.28$0.287$0.2749$0.27491.44M
Sep 15, 2026$0.30$0.3006$0.2825$0.28932.18M
Sep 14, 2026$0.3139$0.3144$0.3009$0.31212.36M
Sep 11, 2026$0.3371$0.3401$0.3058$0.31021.11M
Sep 10, 2026$0.348$0.348$0.3253$0.34941.06K
Sep 9, 2026$0.3321$0.3609$0.3229$0.3422M
Sep 8, 2026$0.344$0.345$0.3317$0.33231.31M
Sep 4, 2026$0.346$0.3496$0.33$0.34961.17M
Sep 3, 2026$0.3705$0.3705$0.3362$0.34992M
Sep 2, 2026$0.38$0.388$0.37$0.37641.92M
Sep 1, 2026$0.4116$0.4179$0.3807$0.39422.34M
Aug 31, 2026$0.4024$0.4506$0.3775$0.43395.01M
Aug 28, 2026$0.45$0.4608$0.4333$0.449316.17M
Aug 27, 2026$0.6477$0.72$0.501$0.501354.11M
Aug 26, 2026$0.45$0.4688$0.3269$0.339262.42M
Aug 25, 2026$0.385$0.409$0.3701$0.3846568.1K
Aug 24, 2026$0.43$0.43$0.3738$0.3911.13M
Aug 21, 2026$0.44$0.45$0.4101$0.4169545.82K
Aug 20, 2026$0.4924$0.5214$0.4349$0.4444531.77K
Aug 19, 2026$0.49$0.523$0.4735$0.4881937.46K

Latest VNRX news

The latest Smart Investors Daily articles mentioning VNRX.

Stock researchCompany · Overview

VNRX research

Overview

Company profile and research snapshot.

Company profile

VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
VNRX recent ratings
DateFirmRatingTarget
Jun 18, 2026Maxim GroupBuy—
Apr 20, 2026D. Boral CapitalHold—
Apr 2, 2026HC Wainwright & Co.Buy—
Mar 31, 2026D. Boral CapitalBuy—
Mar 26, 2026D. Boral CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 10, 2026

Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of an abstract1 at the European Society of Medical Oncology Molecular Analysis for Precision Oncology Conference (ESMO MAP) in London this week. The presentation entitled "Early stage I solid cancer detection by direct ChIP-seq of short CTCF-protected plasma ctDNA" and given by Dr. Andrew Retter, highlights the use of its Capture-Seq™ technology in the detection of early-stage

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By